Immunohistochemical detection of phospho-akt, phospho-bad, her2 and oestrogen receptors α and β in malaysian breast cancer patients

Pathology and Oncology Research

Volumn 16, Issue 2, 2010, Pages 239-248

  Seow, Heng Fong ^a   Yip, Wai Kien ^a   Loh, Hui Woon ^a   Ithnin, Hairuszah ^a   Por, Patricia ^b   Rohaizak, Mohammad ^b,c  

^a UNIVERSITY PUTRA MALAYSIA   (Malaysia)

^b Assunta Hospital   (Malaysia)

^c UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTER   (Malaysia)

Author keywords

Akt; Breast cancer; HER2; Oestrogen receptor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; KI 67 ANTIGEN; PARAFFIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAD; PROTEIN KINASE B; SERINE; THREONINE;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER CELL; CANCER STAGING; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME INACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MALAYSIA; PROTEIN EXPRESSION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADULT; BCL-ASSOCIATED DEATH PROTEIN; BREAST NEOPLASMS; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALAYSIA; MIDDLE AGED; NEOPLASM STAGING; NUCLEAR PROTEINS; ONCOGENE PROTEIN V-AKT; PHOSPHORYLATION; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 77955715690     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12253-009-9216-3     Document Type: Article

References (64)

1. Lim GCC, Halimah Y (2004) Second report of the national cancer registry: cancer incidence in Malaysia 2003. National Cancer Registry, Malaysia
2. Clarke R, Skaar T, Leonessa F et al. (1996) Acquisition of an antiestrogen-resistant phenotype in breast cancer: role of cellular and molecular mechanisms. Cancer Treat Res 87:263-283
3. Ring A, Dowsett M (2004) Mechanisms of tamoxifen resistance. Endocr Relat Cancer 11:643-658
4. Pandolfi PP (2004) Breast cancer-loss of PTEN predicts resistance to treatment. N Engl J Med 351:2337-2338
5. Tokunaga E, Kataoka A, Kimura Y et al. (2006) The association between Akt activation and resistance to hormone therapy in metastatic breast cancer. Eur J Cancer 42:629-635
6. Brognard J, Clark AS, Ni Y et al. (2001) Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61:3986-3997
7. Clark AS, West K, Streicher S et al. (2002) Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 1:707-717
8. Luo Y, Shoemaker AR, Liu X et al. (2005) Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol Cancer Ther 4:977-986
9. Kondapaka SB, Singh SS, Dasmahapatra GP et al. (2003) Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2:1093-1103
10. Jones PF, Jakubowicz T, Hemmings BA (1991) Molecular cloning of a second form of rac protein kinase. Cell Regul 2:1001-1009
11. Bellacosa A, Kumar CC, Di Cristofano A et al. (2005) Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 94:29-86
12. Masure S, Haefner B, Wesselink JJ et al. (1999) Molecular cloning, expression and characterization of the human serine/ threonine kinase Akt-3. Eur J Biochem 265:353-360
13. Cheng JQ, Godwin AK, Bellacosa A et al. (1992) AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/ threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci U S A 89:9267-9271
14. Alessi DR, James SR, Downes CP et al. (1997) Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 7:261-269
15. Stephens L, Anderson K, Stokoe D et al. (1998) Protein kinase B kinases that mediate phosphatidylinositol 3, 4, 5-trisphosphatedependent activation of protein kinase B. Science 279:710-714
16. Sarbassov DD, Guertin DA, Ali SM et al. (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098-1101
17. Hresko RC, Mueckler M (2005) mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem 280:40406-40416
18. Dimmeler S, Fleming I, Fisslthaler B et al. (1999) Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399:601-605
19. Nakanishi K, Sakamoto M, Yasuda J et al. (2002) Critical involvement of the phosphatidylinositol 3-kinase/Akt pathway in anchorage-independent growth and hematogeneous intrahepatic metastasis of liver cancer. Cancer Res 62:2971-2975
20. Altomare DA, Testa JR (2005) Perturbations of the AKT signaling pathway in human cancer. Oncogene 24:7455-7464
21. Wu Y, Mohamed H, Chillar R et al. (2008) Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer. Breast Cancer Res 10:R3
22. Lazennec G, Bresson D, Lucas A et al. (2001) ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology 142:4120-4130
23. Rajnakova A, Goh PM, Chan ST et al. (1997) Expression of differential nitric oxide synthase isoforms in human normal gastric mucosa and gastric cancer tissue. Carcinogenesis 18:1841-1845
24. Endo K, Terada T (2000) Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival. J Hepatol 32:78-84
25. Allred DC, Harvey JM, Berardo M et al. (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155-168
26. Cobleigh MA, Vogel CL, Tripathy D et al. (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648
27. Scheid MP, Marignani PA, Woodgett JR (2002) Multiple phosphoinositide 3-kinase-dependent steps in activation of protein kinase B. Mol Cell Biol 22:6247-6260
28. Nadji M, Gomez-Fernandez C, Ganjei-Azar P et al. (2005) Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol 123:21-27
29. Looi LM, Cheah PL (1998) C-erbB-2 oncoprotein amplification in infiltrating ductal carcinoma of breast relates to high histological grade and loss of oestrogen receptor protein. Malays J Pathol 20:19-23
30. Pavao M, Traish AM (2001) Estrogen receptor antibodies: specificity and utility in detection, localization and analyses of estrogen receptor alpha and beta. Steroids 66:1-16
31. Speirs V, Green CA, Shaaban AM (2008) Oestrogen receptor beta immunohistochemistry: time to get it rightκ J Clin Pathol 61:1150-1151 author reply 1151-2
32. Rhodes A, Jasani B, Balaton AJ et al. (2000) Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening. J Clin Pathol 53:688-696
33. Slamon DJ, Godolphin W, Jones LA et al. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712
34. Chariyalertsak S, Chariyalertsak S, Cheirsilpa A et al. (1996) Immunohistochemical detection of c-erbB-2 oncoprotein in patients with breast cancer. J Med Assoc Thail 79:715-721
35. Almasri NM, Al Hamad M (2005) Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan. Breast Cancer Res 7:R598-R604
36. Rosa FE, Caldeira JR, Felipes J et al. (2008) Evaluation of estrogen receptor alpha and beta and progesterone receptor expression and correlation with clinicopathologic factors and proliferative marker Ki-67 in breast cancers. Hum Pathol 39:720-730
37. Jarzabek K, Koda M, Kozlowski L et al. (2005) Distinct mRNA, protein expression patterns and distribution of oestrogen receptors alpha and beta in human primary breast cancer: correlation with proliferation marker Ki-67 and clinicopathological factors. Eur J Cancer 41:2924-2934
38. Finlin BS, Gau CL, Murphy GA et al. (2001) RERG is a novel rasrelated, estrogen-regulated and growth-inhibitory gene in breast cancer. J Biol Chem 276:42259-42267
39. Guo S, Sonenshein GE (2004) Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway. Mol Cell Biol 24:8681-8690
40. Fuqua SA, Schiff R, Parra I et al. (2003) Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res 63:2434-2439
41. Skliris GP, Munot K, Bell SM et al. (2003) Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. J Pathol 201:213-220
42. Fox EM, Davis RJ, Shupnik MA (2008) ERbeta in breast cancer-onlooker, passive player, or active protectorκ Steroids 73:1039-1051
43. Al-Bazz YO, Underwood JC, Brown BL et al. (2009) Prognostic significance of Akt, phospho-Akt and BAD expression in primary breast cancer. Eur J Cancer 45:694-704
44. Bose S, Chandran S, Mirocha JM et al. (2006) The Akt pathway in human breast cancer: a tissue-array-based analysis. Mod Pathol 19:238-245
45. Ahmad S, Singh N, Glazer RI (1999) Role of AKT1 in 17betaestradiol- and insulin-like growth factor I (IGF-I)-dependent proliferation and prevention of apoptosis in MCF-7 breast carcinoma cells. Biochem Pharmacol 58:425-430
46. Tsai EM, Wang SC, Lee JN et al. (2001) Akt activation by estrogen in estrogen receptor-negative breast cancer cells. Cancer Res 61:8390-8392
47. Kirkegaard T, Witton CJ, McGlynn LM et al. (2005) AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 207:139-146
48. Lenferink AE, Busse D, Flanagan WM et al. (2001) ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways. Cancer Res 61:6583-6591
49. Hermanto U, Zong CS, Wang LH (2001) ErbB2-overexpressing human mammary carcinoma cells display an increased requirement for the phosphatidylinositol 3-kinase signaling pathway in anchorage-independent growth. Oncogene 20:7551-7562
50. Pianetti S, Arsura M, Romieu-Mourez R et al. (2001) Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN. Oncogene 20:1287-1299
51. Zhang G, He B, Weber GF (2003) Growth factor signaling induces metastasis genes in transformed cells: molecular connection between Akt kinase and osteopontin in breast cancer. Mol Cell Biol 23:6507-6519
52. Panigrahi AR, Pinder SE, Chan SY et al. (2004) The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. J Pathol 204:93-100
53. Schmitz KJ, Otterbach F, Callies R et al. (2004) Prognostic relevance of activated Akt kinase in node-negative breast cancer: a clinicopathological study of 99 cases. Mod Pathol 17:15-21
54. Stal O, Perez-Tenorio G, Akerberg L et al. (2003) Akt kinases in breast cancer and the results of adjuvant therapy. Breast Cancer Res 5:R37-R44
55. Zhou X, Tan M, Stone Hawthorne Vet al. (2004) Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 10:6779-6788
56. Hill MM, Hemmings BA (2002) Inhibition of protein kinase B/ Akt. implications for cancer therapy. Pharmacol Ther 93:243-251
57. Zha J, Harada H, Yang E et al. (1996) Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 87:619-628
58. Fernando RI, Wimalasena J (2004) Estradiol abrogates apoptosis in breast cancer cells through inactivation of BAD: Ras-dependent nongenomic pathways requiring signaling through ERK and Akt. Mol Biol Cell 15:3266-3284
59. Krasilnikov MA (2000) Phosphatidylinositol-3 kinase dependent pathways: the role in control of cell growth, survival, and malignant transformation. Biochemistry (Mosc) 65:59-67
60. Liao Y, Hung MC (2003) Regulation of the activity of p38 mitogen-activated protein kinase by Akt in cancer and adenoviral protein E1A-mediated sensitization to apoptosis. Mol Cell Biol 23:6836-6848
61. Yonemori K, Tsuta K, Shimizu C, et al. (2009) Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy. Med Oncol 26:344-349
62. Klauber-DeMore N (2005) Tumor biology of breast cancer in young women. Breast Dis 23:9-15 (Pubitemid 44308923)
63. Hartley MC, McKinley BP, Rogers EA et al. (2006) Differential expression of prognostic factors and effect on survival in young (
64. Hussein MR, Abd-Elwahed SR, Abdulwahed AR (2008) Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast. Cell Biol Int 32:698-707